Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Analysis of novel biomarkers in the pathobiology of prostate cancer

D'Antonio, Katherine Elizabeth Bright (2009) Analysis of novel biomarkers in the pathobiology of prostate cancer. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

Primary Text

Download (6MB) | Preview


The process of developing a greater understanding of the fundamental molecular mechanisms involved in prostate carcinogenesis will provide insights into the questions that still plague the field of prostate cancer research. The goal of this study was to identify altered genes that may have utility either as biomarkers, for improved diagnostic or prognostic application, or as novel targets important in the pathobiology of prostate cancer. We hypothesize that an improved understanding of the genomic and proteomic alterations associated with prostate cancer will facilitate the identification of novel biomarkers and molecular pathways critical to prostate carcinogenesis. In order to enhance our knowledge of the molecular alterations associated with prostate cancer, our laboratory performed microarray analysis comparing gene expression in healthy normal prostate to that in prostate cancer tissue. Of the greater than 400 genes with significantly altered expression identified in our study, MT2A, Tacc2, Nell2, FosB, PCP4, and Cyr61 were selected for further evaluation to confirm expression changes and evaluate their potential impact in prostate cancer. Analysis of MT2A, Tacc2, and Nell2 expression patterns failed to demonstrate significant changes between prostate cancer and donor prostate tissue and, therefore, these results do not support their further development as prostate cancer biomarkers. We demonstrated that PCP4 was expressed predominently in the stromal compartment of the prostate and was expressed at similar levels in the stroma of normal and prostate cancer tissue. Interestingly, protein expression of PCP4 in a panel of colon cancer tissues was dramatically higher in adenoma and adenocarcinoma tissues compared to donor and benign colon tissue and, consequently, we feel that PCP4 has more potential as a biomarker in colon cancer than in prostate cancer. We also demonstrated that FosB and Cyr61 were upregulated in prostate cancer tissues over donor prostate tissues. Based on expression analysis of FosB and expression and functional analysis of Cyr61, we believe that these two targets have the greatest potental to be functionally significant in the etiology of prostate cancer.


Social Networking:
Share |


Item Type: University of Pittsburgh ETD
Status: Unpublished
CreatorsEmailPitt UsernameORCID
D'Antonio, Katherine Elizabeth
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairLi,
Committee MemberPflug,
Committee MemberJohnson, Danjohnsond@pitt.eduJOHNSOND
Committee MemberMichalopoulos, Georgemichalopoulosgk@upmc.eduMICHAL
Committee MemberGetzenberg,
Date: 17 April 2009
Date Type: Completion
Defense Date: 13 April 2009
Approval Date: 17 April 2009
Submission Date: 17 April 2009
Access Restriction: No restriction; Release the ETD for access worldwide immediately.
Institution: University of Pittsburgh
Schools and Programs: School of Medicine > Cellular and Molecular Pathology
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: biomarker; colon cancer; Cyr61; PCP4; prostate cancer
Other ID:, etd-04172009-105358
Date Deposited: 10 Nov 2011 19:38
Last Modified: 19 Dec 2016 14:35


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item